Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00197015 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,474
- Enrollment target
NCT00197015 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,474 participants.
The verdict
NCT00197015, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,474 participants
- Enrollment target
Study Summary
This is a study to evaluate the immune response and safety of GSK Biologicals 2-dose inactivated hepatitis A vaccine when administered with a measles/mumps/rubella vaccine and a varicella (chickenpox) vaccine in children as young as 15 months of age. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Interventions
- BIOLOGICAL Havrix®
- BIOLOGICAL M-M-R®II
- BIOLOGICAL VARIVAX®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,474 participants |
| Start Date | 2003-10-06 |
| Est. Completion | 2009-06-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00197015
The ClinicalTrials.gov registry entry for NCT00197015 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,474 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Havrix® is the first listed.
NCT00197015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00197015 about?
NCT00197015 is a clinical study titled "Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children". This is a study to evaluate the immune response and safety of GSK Biologicals 2-dose inactivated hepatitis A vaccine when administered with a measles/mumps/rubella vaccine and a varicella (chickenpox) vaccine in children as young as 15 months of age. The Protocol Posting has been updated in order t...
What is the current status of trial NCT00197015?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,474 participants. The study started on 2003-10-06. Estimated completion is 2009-06-09.
What interventions are being tested in trial NCT00197015?
The interventions under investigation include: Havrix® (BIOLOGICAL), M-M-R®II (BIOLOGICAL), VARIVAX® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00197015?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.